Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models.
ADCC
CDC
EpCAM monoclonal antibody
colorectal cancer
Journal
International journal of molecular medicine
ISSN: 1791-244X
Titre abrégé: Int J Mol Med
Pays: Greece
ID NLM: 9810955
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
14
08
2022
accepted:
07
12
2022
entrez:
20
1
2023
pubmed:
21
1
2023
medline:
24
1
2023
Statut:
ppublish
Résumé
Epithelial cell adhesion molecule (EpCAM) is a type I transmembrane glycoprotein, which is highly expressed on tumor cells. As EpCAM plays a crucial role in cell adhesion, survival, proliferation, stemness, and tumorigenesis, it has been considered as a promising target for tumor diagnosis and therapy. Anti‑EpCAM monoclonal antibodies (mAbs) have been developed and have previously demonstrated promising outcomes in several clinical trials. An anti‑EpCAM mAb, EpMab‑37 (mouse IgG
Identifiants
pubmed: 36660940
doi: 10.3892/ijmm.2023.5221
pii: 18
pmc: PMC9869728
doi:
pii:
Substances chimiques
Antibodies, Monoclonal
0
Epithelial Cell Adhesion Molecule
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Radiat Oncol. 2020 Jun 1;15(1):137
pubmed: 32487218
Cancer Cell Int. 2010 Nov 02;10:44
pubmed: 21044305
Oncol Rep. 2020 Nov;44(5):1949-1960
pubmed: 33000243
Br J Clin Pharmacol. 2010 Jun;69(6):617-25
pubmed: 20565453
Arch Esp Urol. 2021 Sep;74(7):681-691
pubmed: 34472437
Clin Cancer Res. 2011 May 15;17(10):3157-69
pubmed: 21372224
Monoclon Antib Immunodiagn Immunother. 2021 Aug;40(4):191-195
pubmed: 34283639
Biochem Biophys Rep. 2020 Aug 30;24:100801
pubmed: 32923698
Cancer Immunol Res. 2016 Mar;4(3):259-68
pubmed: 26822025
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352
pubmed: 32300252
Oncotarget. 2018 Apr 27;9(32):22480-22497
pubmed: 29854293
Oncol Rep. 2022 Sep;48(3):
pubmed: 35856438
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Monoclon Antib Immunodiagn Immunother. 2021 Aug;40(4):162-167
pubmed: 34424761
Int J Mol Sci. 2017 Aug 31;18(9):
pubmed: 28858218
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818767936
pubmed: 29649929
Monoclon Antib Immunodiagn Immunother. 2022 Jun;41(3):142-149
pubmed: 35666554
Mol Ther Oncolytics. 2022 Jul 20;26:265-274
pubmed: 35991754
Br J Cancer. 2018 Aug;119(3):296-302
pubmed: 29988111
Br J Cancer. 2007 Feb 12;96(3):417-23
pubmed: 17211480
Monoclon Antib Immunodiagn Immunother. 2017 Jun;36(3):104-112
pubmed: 28504613
Monoclon Antib Immunodiagn Immunother. 2022 Feb;41(1):1-7
pubmed: 35225663
Cancer Chemother Pharmacol. 2015 May;75(5):1065-73
pubmed: 25814216
Cells. 2021 Dec 20;10(12):
pubmed: 34944112
MAbs. 2010 Mar-Apr;2(2):129-36
pubmed: 20190561
MAbs. 2020 Jan-Dec;12(1):1703531
pubmed: 31847708
Cancer Res. 2021 Sep 15;81(18):4641-4651
pubmed: 34145037
Proc Natl Acad Sci U S A. 1979 Mar;76(3):1438-42
pubmed: 286328
Monoclon Antib Immunodiagn Immunother. 2021 Aug;40(4):177-183
pubmed: 34424762
Antibodies (Basel). 2022 Jun 08;11(2):
pubmed: 35735360
Oncol Rep. 2020 Dec;44(6):2517-2526
pubmed: 33125138
Int J Mol Sci. 2021 Sep 30;22(19):
pubmed: 34638982
Nat Biotechnol. 2013 Jun;31(6):539-44
pubmed: 23609047
Biochem Biophys Rep. 2020 Oct 10;24:100826
pubmed: 33088928
Sci Rep. 2014 Aug 01;4:5924
pubmed: 25080943
Exp Hematol Oncol. 2017 May 2;6:12
pubmed: 28469973
Biotechnol Bioeng. 2004 Sep 5;87(5):614-22
pubmed: 15352059
Am J Pathol. 2007 Aug;171(2):386-95
pubmed: 17600130
Cancer Sci. 2018 Aug;109(8):2539-2548
pubmed: 29900633
Curr Protoc. 2021 Nov;1(11):e296
pubmed: 34787960
Monoclon Antib Immunodiagn Immunother. 2021 Aug;40(4):149-155
pubmed: 34424763
Monoclon Antib Immunodiagn Immunother. 2022 Apr;41(2):67-73
pubmed: 35377239
Genes Cells. 2022 Sep;27(9):549-558
pubmed: 35790497
J Clin Oncol. 1998 May;16(5):1788-94
pubmed: 9586892
Dev Cell. 2013 Nov 11;27(3):263-77
pubmed: 24183651
Biomedicines. 2021 Aug 30;9(9):
pubmed: 34572297
Biomolecules. 2020 Jun 30;10(7):
pubmed: 32630017
J Immunol. 2007 Jul 15;179(2):1362-8
pubmed: 17617629
Monoclon Antib Immunodiagn Immunother. 2021 Aug;40(4):156-161
pubmed: 34283655
Biochem Biophys Rep. 2018 Nov 24;17:23-26
pubmed: 30519645
MAbs. 2018 Jul;10(5):693-711
pubmed: 29733746
J Biol Chem. 2003 Jan 31;278(5):3466-73
pubmed: 12427744
Nat Rev Immunol. 2021 Oct;21(10):680-686
pubmed: 34518662
N Engl J Med. 2019 Feb 21;380(8):741-751
pubmed: 30786188
Nat Commun. 2014 Aug 28;5:4764
pubmed: 25163760
Cancers (Basel). 2020 May 19;12(5):
pubmed: 32438548
Cancer Res. 2009 Jul 15;69(14):5627-9
pubmed: 19584271
Monoclon Antib Immunodiagn Immunother. 2022 Feb;41(1):20-26
pubmed: 35225660
Cancer Med. 2017 Apr;6(4):768-777
pubmed: 28332312
Lancet. 1982 Apr 3;1(8275):762-5
pubmed: 6121224
Cells. 2020 May 31;9(6):
pubmed: 32486423
Biomolecules. 2021 Jun 29;11(7):
pubmed: 34209658
Trends Pharmacol Sci. 2022 May;43(5):378-391
pubmed: 35272862
Oncol Lett. 2020 Dec;20(6):383
pubmed: 33154781
Monoclon Antib Immunodiagn Immunother. 2016 Oct;35(5):263-266
pubmed: 27788030
Monoclon Antib Immunodiagn Immunother. 2020 Aug;39(4):135-139
pubmed: 32644843
Curr Cancer Drug Targets. 2018;18(9):857-868
pubmed: 29295696
Monoclon Antib Immunodiagn Immunother. 2022 Dec;41(6):311-319
pubmed: 35483059
Int J Mol Med. 2018 Oct;42(4):1771-1785
pubmed: 30015855
Cells. 2022 Feb 07;11(3):
pubmed: 35159384
Monoclon Antib Immunodiagn Immunother. 2022 Feb;41(1):8-14
pubmed: 35225667
Monoclon Antib Immunodiagn Immunother. 2020 Apr;39(2):37-44
pubmed: 32182186
Oncol Lett. 2020 Apr;19(4):2809-2816
pubmed: 32218834
Nat Commun. 2022 Aug 8;13(1):4633
pubmed: 35941104